BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 545 filers reported holding BIO-TECHNE CORP in Q1 2024. The put-call ratio across all filers is 1.05 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $205,080,929 | +10.1% | 2,862,260 | +8.2% | 0.30% | +13.8% |
Q1 2024 | $186,267,144 | +0.6% | 2,646,216 | +10.3% | 0.27% | -3.9% |
Q4 2023 | $185,132,071 | +19.5% | 2,399,327 | +3.0% | 0.28% | +7.3% |
Q3 2023 | $154,880,694 | -10.3% | 2,329,033 | +9.4% | 0.26% | -0.8% |
Q2 2023 | $172,747,141 | +25.5% | 2,129,001 | +14.8% | 0.26% | +23.0% |
Q1 2023 | $137,618,963 | -6.0% | 1,854,953 | +5.0% | 0.21% | -13.1% |
Q4 2022 | $146,458,492 | +25.7% | 1,767,115 | +330.8% | 0.24% | +22.5% |
Q3 2022 | $116,501,000 | -12.9% | 410,216 | +6.3% | 0.20% | -6.5% |
Q2 2022 | $133,802,000 | +7.6% | 385,997 | +34.4% | 0.21% | +28.1% |
Q1 2022 | $124,399,000 | +9417.9% | 287,268 | +11267.9% | 0.17% | +8250.0% |
Q4 2021 | $1,307,000 | +2.3% | 2,527 | -4.1% | 0.00% | 0.0% |
Q3 2021 | $1,277,000 | +87.0% | 2,635 | +73.8% | 0.00% | +100.0% |
Q2 2021 | $683,000 | +11.2% | 1,516 | -63.5% | 0.00% | -50.0% |
Q2 2018 | $614,000 | -95.3% | 4,150 | -95.2% | 0.00% | -93.9% |
Q1 2018 | $13,132,000 | -76.3% | 86,941 | -79.6% | 0.03% | -75.4% |
Q4 2017 | $55,319,000 | -19.8% | 427,006 | -25.1% | 0.13% | -64.0% |
Q3 2017 | $68,944,000 | -4.6% | 570,301 | -7.3% | 0.37% | -7.5% |
Q2 2017 | $72,284,000 | +12.5% | 615,187 | -2.7% | 0.40% | +6.9% |
Q1 2017 | $64,273,000 | +10.3% | 632,301 | +11.5% | 0.38% | +7.7% |
Q4 2016 | $58,294,000 | +1.4% | 566,901 | +8.0% | 0.35% | -2.8% |
Q3 2016 | $57,476,000 | +10.4% | 524,894 | +13.7% | 0.36% | +22.1% |
Q2 2016 | $52,064,000 | +8.5% | 461,681 | -9.0% | 0.29% | -32.4% |
Q1 2016 | $47,964,000 | -5.1% | 507,444 | -9.7% | 0.44% | +38.5% |
Q4 2015 | $50,568,000 | +105.1% | 561,862 | +110.7% | 0.31% | +109.3% |
Q3 2015 | $24,652,000 | -8.1% | 266,620 | -2.1% | 0.15% | +3.4% |
Q2 2015 | $26,815,000 | -32.8% | 272,320 | -31.5% | 0.14% | -31.0% |
Q1 2015 | $39,895,000 | -6.1% | 397,800 | -13.5% | 0.21% | -3.2% |
Q4 2014 | $42,504,000 | – | 460,000 | – | 0.22% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 54,711 | $28,304,000 | 8.66% |
Montanaro Asset Management Ltd | 104,450 | $54,036,000 | 5.45% |
Ownership Capital B.V. | 891,186 | $461,046,000 | 4.99% |
Sandhill Capital Partners LLC | 121,682 | $62,951,000 | 4.89% |
Brown Capital Management | 986,803 | $510,513,000 | 4.22% |
STONE RUN CAPITAL, LLC | 22,300 | $11,536,000 | 3.73% |
DF DENT & CO INC | 681,416 | $352,524,000 | 3.54% |
MAIRS & POWER INC | 653,815 | $338,244,000 | 3.13% |
Summit Creek Advisors LLC | 57,959 | $29,985,000 | 3.01% |
Aristotle Atlantic Partners, LLC | 95,597 | $49,456,000 | 2.87% |